FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313232090> ?p ?o ?g. }

• W4313232090 endingPage "199" @default.
• W4313232090 startingPage "199" @default.
• W4313232090 abstract "Apixaban and rivaroxaban require lead-in dosing for 7 and 21 days, respectively, when treating venous thromboembolism (VTE). However, no evidence exists to support subtracting parenteral anticoagulation days from total lead-in dosing. A multicenter study was conducted, including adult patients with acute VTE who received apixaban or rivaroxaban. The patients were grouped as follows. The recommended group received oral lead-in anticoagulant for the full recommended duration. The mixed group received lead-in therapy as parenteral with oral anticoagulant. The incidence of recurrent VTE (rVTE) and major bleeding (MB) within 90 days were the main outcomes. Of the 368 included patients, 47.8% received apixaban, and 52.2% received rivaroxaban. The recommended lead-in was used in 296 patients (80.4%), whereas 72 (19.6%) received the mixed-lead-in regimen. Five patients had rVTE events within 90 days; two occurred during hospitalization in the recommended group versus none in the mixed group (0.7% vs. 0.0%; p = 1.000). After discharge, two events occurred in the recommended group and one in the mixed group (0.7% vs. 1.4%; p = 0.481). In terms of MB, 24 events occurred in 21 patients within 90 days. During hospitalization, 11 events occurred in the recommended group and seven in the mixed group (3.7% vs. 9.7%; p = 0.060). After discharge, five more events occurred in the recommended group and one in the mixed group (1.4% vs. 1.7%; p = 1.000). The mixed-lead-in regimen is safe and effective in comparison with the recommended-lead-in regimen." @default.
• W4313232090 created "2023-01-06" @default.
• W4313232090 creator A5005774540 @default.
• W4313232090 creator A5006303327 @default.
• W4313232090 creator A5027971970 @default.
• W4313232090 creator A5032982170 @default.
• W4313232090 creator A5035845099 @default.
• W4313232090 creator A5040999876 @default.
• W4313232090 creator A5046615489 @default.
• W4313232090 creator A5049452752 @default.
• W4313232090 creator A5061048922 @default.
• W4313232090 creator A5066482907 @default.
• W4313232090 creator A5073184728 @default.
• W4313232090 creator A5083463342 @default.
• W4313232090 date "2022-12-27" @default.
• W4313232090 modified "2023-10-16" @default.
• W4313232090 title "Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study" @default.
• W4313232090 cites W106352447 @default.
• W4313232090 cites W2016362027 @default.
• W4313232090 cites W2018856451 @default.
• W4313232090 cites W2028762958 @default.
• W4313232090 cites W2075359369 @default.
• W4313232090 cites W2112681385 @default.
• W4313232090 cites W2115787552 @default.
• W4313232090 cites W2130199362 @default.
• W4313232090 cites W2134430286 @default.
• W4313232090 cites W2154778872 @default.
• W4313232090 cites W2160625453 @default.
• W4313232090 cites W2166402206 @default.
• W4313232090 cites W2971121646 @default.
• W4313232090 cites W2989714602 @default.
• W4313232090 cites W3090209681 @default.
• W4313232090 cites W3112865739 @default.
• W4313232090 cites W3189638887 @default.
• W4313232090 cites W4225820476 @default.
• W4313232090 doi "https://doi.org/10.3390/jcm12010199" @default.
• W4313232090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36615002" @default.
• W4313232090 hasPublicationYear "2022" @default.
• W4313232090 type Work @default.
• W4313232090 citedByCount "0" @default.
• W4313232090 crossrefType "journal-article" @default.
• W4313232090 hasAuthorship W4313232090A5005774540 @default.
• W4313232090 hasAuthorship W4313232090A5006303327 @default.
• W4313232090 hasAuthorship W4313232090A5027971970 @default.
• W4313232090 hasAuthorship W4313232090A5032982170 @default.
• W4313232090 hasAuthorship W4313232090A5035845099 @default.
• W4313232090 hasAuthorship W4313232090A5040999876 @default.
• W4313232090 hasAuthorship W4313232090A5046615489 @default.
• W4313232090 hasAuthorship W4313232090A5049452752 @default.
• W4313232090 hasAuthorship W4313232090A5061048922 @default.
• W4313232090 hasAuthorship W4313232090A5066482907 @default.
• W4313232090 hasAuthorship W4313232090A5073184728 @default.
• W4313232090 hasAuthorship W4313232090A5083463342 @default.
• W4313232090 hasBestOaLocation W43132320901 @default.
• W4313232090 hasConcept C120665830 @default.
• W4313232090 hasConcept C121332964 @default.
• W4313232090 hasConcept C126322002 @default.
• W4313232090 hasConcept C141071460 @default.
• W4313232090 hasConcept C23131810 @default.
• W4313232090 hasConcept C2776301958 @default.
• W4313232090 hasConcept C2777288759 @default.
• W4313232090 hasConcept C2778205648 @default.
• W4313232090 hasConcept C2778661090 @default.
• W4313232090 hasConcept C2779161974 @default.
• W4313232090 hasConcept C2780638905 @default.
• W4313232090 hasConcept C2781413609 @default.
• W4313232090 hasConcept C42219234 @default.
• W4313232090 hasConcept C61511704 @default.
• W4313232090 hasConcept C71924100 @default.
• W4313232090 hasConceptScore W4313232090C120665830 @default.
• W4313232090 hasConceptScore W4313232090C121332964 @default.
• W4313232090 hasConceptScore W4313232090C126322002 @default.
• W4313232090 hasConceptScore W4313232090C141071460 @default.
• W4313232090 hasConceptScore W4313232090C23131810 @default.
• W4313232090 hasConceptScore W4313232090C2776301958 @default.
• W4313232090 hasConceptScore W4313232090C2777288759 @default.
• W4313232090 hasConceptScore W4313232090C2778205648 @default.
• W4313232090 hasConceptScore W4313232090C2778661090 @default.
• W4313232090 hasConceptScore W4313232090C2779161974 @default.
• W4313232090 hasConceptScore W4313232090C2780638905 @default.
• W4313232090 hasConceptScore W4313232090C2781413609 @default.
• W4313232090 hasConceptScore W4313232090C42219234 @default.
• W4313232090 hasConceptScore W4313232090C61511704 @default.
• W4313232090 hasConceptScore W4313232090C71924100 @default.
• W4313232090 hasFunder F4320322484 @default.
• W4313232090 hasIssue "1" @default.
• W4313232090 hasLocation W43132320901 @default.
• W4313232090 hasLocation W43132320902 @default.
• W4313232090 hasLocation W43132320903 @default.
• W4313232090 hasOpenAccess W4313232090 @default.
• W4313232090 hasPrimaryLocation W43132320901 @default.
• W4313232090 hasRelatedWork W1984954114 @default.
• W4313232090 hasRelatedWork W2576538605 @default.
• W4313232090 hasRelatedWork W2586961766 @default.
• W4313232090 hasRelatedWork W2724472742 @default.
• W4313232090 hasRelatedWork W2741829680 @default.
• W4313232090 hasRelatedWork W2895090492 @default.
• W4313232090 hasRelatedWork W2908436399 @default.

• next